细胞外SPARC协同TGF-β信号诱导系统性硬化症患者真皮成纤维细胞的促纤维化活化
本研究分析外源性SPARC对系统性硬化症(SSc)患者真皮成纤维细胞的促纤维化作用。SSc患者来源的成纤维细胞经外源性SPARC刺激后,胶原I、胶原IV、纤连蛋白1、TGF-β及SPARC的mRNA和蛋白表达均升高,而健康对照成纤维细胞无此反应;该效应依赖TGF-β信号,抑制TGF-β信号可消除SPARC诱导的促纤维化基因表达。
要点
- 外源性SPARC仅诱导SSc患者真皮成纤维细胞表达胶原I、胶原IV、纤连蛋白1、TGF-β及SPARC。
- SPARC诱导SMAD2酪氨酸激酶活化,抑制TGF-β信号可消除其促纤维化基因表达。
- SPARC的促纤维化效应依赖TGF-β信号,提示其可作为SSc抗纤维化治疗靶点。
核心结论
- 外源性SPARC是促进SSc病理的促纤维化介质,但其作用依赖TGF-β信号。
- SPARC可能成为减少SSc患者纤维化的治疗靶点,即使在疾病晚期。
研究设计与样本
- 研究比较健康对照与SSc患者来源的真皮成纤维细胞,分别单独或联合TGF-β1刺激,并在有无TGF受体1抑制剂条件下培养。
- 采用定量PCR和western blot检测细胞外基质成分及其他纤维化相关介质的mRNA和蛋白表达。
主要发现
- 外源性SPARC诱导SSc患者真皮成纤维细胞中胶原I、胶原IV、纤连蛋白1、TGF-β及SPARC的mRNA和蛋白表达,而健康对照成纤维细胞无此反应。
- 外源性SPARC诱导酪氨酸激酶SMAD2活化。
- 抑制TGF-β信号可消除SPARC在SSc成纤维细胞中诱导的促纤维化基因表达。
临床怎么用
- SPARC的促纤维化作用依赖TGF-β信号,靶向SPARC或TGF-β通路可能有助于减轻SSc纤维化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: SSc is an autoimmune disease characterized by inflammation, vascular injury and excessive fibrosis in multiple organs. Secreted protein acidic and rich in cysteine (SPARC) is a matricellular glycoprotein that regulates processes involved in SSc pathology, such as inflammation and fibrosis. In vivo and in vitro studies have implicated SPARC in SSc, but it is unclear if the pro-fibrotic effects of SPARC on fibroblasts are a result of intracellular signalling or fibroblast interactions with extracellular SPARC hampering further development of SPARC as a potential therapeutic target. This study aimed to analyse the potential role of exogenous SPARC as a regulator of fibrosis in SSc. METHODS: Dermal fibroblasts from both healthy controls and SSc patients were stimulated with SPARC alone or in combination with TGF-β1, in the absence or presence of a TGF receptor 1 inhibitor. mRNA and protein expression of extracellular matrix components and other fibrosis-related mediators were measured by quantitative PCR and western blot. RESULTS: Exogenous SPARC induced mRNA and protein expression of collagen I, collagen IV, fibronectin 1, TGF-β and SPARC by dermal fibroblasts from SSc patients, but not from healthy controls. Importantly, exogenous SPARC induced the activation of the tyrosine kinase SMAD2 and pro-fibrotic gene expression induced by SPARC in SSc fibroblasts was abrogated by inhibition of TGF-β signalling. CONCLUSION: These results indicate that exogenous SPARC is an important pro-fibrotic mediator contributing to the pathology driving SSc but in a TGF-β dependent manner. Therefore, SPARC could be a promising therapeutic target for reducing fibrosis in SSc patients, even in late states of the disease.
引用
- Carvalheiro T, Malvar Fernández B, Ottria A, et al. Extracellular SPARC cooperates with TGF-β signalling to induce pro-fibrotic activation of systemic sclerosis patient dermal fibroblasts. Rheumatology (Oxford). 2020. PMID: 31840182. doi:10.1093/rheumatology/kez583
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。